Search results
Results from the WOW.Com Content Network
Bambuterol is a long-acting β adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. Commercially, the AstraZeneca pharmaceutical company produces and markets bambuterol as Bambec and Oxeol .
Inhaled short-acting β2-adrenergic agonists, such as terbutaline and salbutamol, are the first-line drugs indicated for asthma exacerbation for all patients to provide rapid bronchodilating effects. [ 1 ] [ 2 ] Short-acting β2-adrenergic agonists can be delivered by different devices, for example, nebulizers and metered-dose inhalers .
Terbutaline, sold under the brand names Bricanyl and Marex among others, is a β 2 adrenergic receptor agonist, used as a "reliever" inhaler in the management of asthma symptoms and as a tocolytic (anti-contraction medication) to delay preterm labor for up to 48 hours.
Related: Benadryl for Dogs: Side Effects of Long-Term Use. Signs of Benadryl Overdose in Dogs. ... The LD50 is when half the dogs die at that dose, so the toxic dose may be a lot lower, and if ...
More severe effects, such as pulmonary edema, myocardial ischemia, and cardiac arrhythmia, are exceptional.) [6] [7] [1] Overuse of β 2 agonists and asthma treatment without proper inhaled corticosteroid use has been associated with an increased risk of asthma exacerbations and asthma-related hospitalizations. [8]
Patients who are suffering from chronic inflammatory lung diseases such as asthma or COPD may be treated with medication targeted to induce more smooth muscle relaxation in the lungs and less contraction of the heart, including first-generation drugs like salbutamol (albuterol) and later-generation medications in the same class.
This compound had a similar effect as adrenalin but fewer side effects were found. In 1949 isoproterenol was used generally to treat asthma patients, given sublingually or inhaled. [1] The first pressurized metered-dose inhaler was introduced in 1956. This was much more convenient for patients than the previously used squeeze-bulb inhalers.
The proposed mechanism is that while LABAs relieve asthma symptoms, they can also promote bronchial inflammation and sensitivity without warning. [23] On February 18, 2011, the FDA issued a safety alert for long-acting β agonists. [24]